Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


MEPs Slate EU Industry Practices In Report On Barriers To Medicines Access

Executive Summary

The European Parliament’s environment and public health committee has produced a set of recommendations for a new approach to tackling barriers to medicines in the EU. There’s a particular focus on pricing strategies, intellectual property, and delays to generic competition.


Related Content

Pharma Attacked For “Playing The System” Of EU Pediatric Rewards
MEPs And Health Advocates Pile The Pressure On EU Drug Pricing
UN Panel Report: Positions Still Polarized Over Medicines Access Barriers
EU Pay-For-Delay Ruling Against Lundbeck Sends Signal To Others, Including UK Competition Body
NGOs Urge EU Ministers To Resist 'Industry Pressure' and Reform RnD Model, Raise Regulatory Standards


What to read next




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts